Study on the Efficacy, Safety and Cost-effectiveness of Cadonilimab in the Treatment of Cervical Cancer
Cadonilimab, a PD-1/CTLA-4 bi-specific antibody, is being developed by Akeso, Inc. for the treatment of a range of solid tumors, including cervical cancer, lung cancer, gastric/gastroesophageal junction cancer, liver cancer and nasopharyngeal cancer. Cadonilimab was approved in China in June 2022 for use in patients with relapsed or metastatic cervical cancer who have progressed on or after platinum-based chemotherapy. The clinicopathological data of patients with persistent, recurrent or metastatic cervical cancer treated with Cadonilimab were collected, and medical images (magnetic resonance, CT, etc.) before and after treatment were followed up, and the efficacy was evaluated according to RECIST standards. The incidence and severity of adverse events and clinically significant abnormal laboratory test results were collected to evaluate the safety of the drug. Survival benefit analysis is conducted based on the patient's survival time and medical expenses.
• •Persistent, recurrent or metastatic cervical cancer;
‣ The pathological types are squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma;
⁃ No combination with other multiple primary cancers;
⁃ MRI before treatment Or CT examination, according to RECIST evaluation standards, there is at least one measurable lesion;
⁃ ECOG score 0-1 points.
⁃ Subjects gave informed consent, voluntarily cooperated with clinical follow-up, and signed informed consent forms.